The recruitment of distinct transcriptional complexes, depending on the FOXE1 variant(s) allele(s), has been proposed as a mechanism to explain FOXE1’s association with the thyroid cancer risk, with rs1867277 A allele leading to the enhanced activation of the FOXE1 promoter [13], while rs7850258 A allele showing lower enhancer activity than the G allele, in vitro [28]. This evidence concerns the gene FOXE1 and thyroid gland carcinoma.